Canada Life’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Canada Life’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,018	Closed	-$21K	–	2088
2024 Q2	$21K	Hold	5,018	–	–	﹤0.01%	2030
2024 Q1	$79K	Hold	5,018	–	–	﹤0.01%	1971
2023 Q4	$76K	Hold	5,018	–	–	﹤0.01%	1999
2023 Q3	$101K	Buy	5,018 +3,839	+326%	+$97.4K	﹤0.01%	1960
2023 Q2	$33K	Sell	1,179 -1,032	-47%	-$24.8K	﹤0.01%	2057
2023 Q1	$38K	Hold	2,211	–	–	﹤0.01%	2110
2022 Q4	$45K	Hold	2,211	–	–	﹤0.01%	2092
2022 Q3	$48K	Hold	2,211	–	–	﹤0.01%	2102
2022 Q2	$62K	Buy	2,211 +1,046	+90%	+$27.7K	﹤0.01%	2015
2022 Q1	$57K	Hold	1,165	–	–	﹤0.01%	2126
2021 Q4	$98K	Hold	1,165	–	–	﹤0.01%	2015
2021 Q3	$78K	Hold	1,165	–	–	﹤0.01%	2114
2021 Q2	$62K	Hold	1,165	–	–	﹤0.01%	2206
2021 Q1	$50K	Hold	1,165	–	–	﹤0.01%	2297
2020 Q4	$60K	Buy	+1,165	New	+$52.5K	﹤0.01%	2224

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Canada Life's ZNTL Position: Q3 2024 in Review

Canada Life sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 5,018 shares — an estimated $21K sold.

Canada Life first reported a position in ZNTL in Q4 2020 and held it in 15 quarters. The position peaked at $101K in Q3 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

Canada Life reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Canada Life sold 5,018 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $21K.
Canada Life first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 15 quarters.
Canada Life's Zentalis Pharmaceuticals position peaked at $101K in Q3 2023.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Canada Life's 13F filing for Q3 2024, filed 13 Nov 2024.